Company intelligence / Profile preview

GelMEDIX

Cambridge, Massachusetts, United Statesgelmedix.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

GelMEDIX’s lead program uses a hydrogel-based cell therapy designed to restore vision in patients with dry age-related macular degeneration (AMD) and geographic atrophy. Another advanced program focuses on a sustained-release corticosteroid subconjunctival implant for ocular inflammation. No published clinical results yet; programs are in preclinical or IND-enabling stages.

Therapeutic areas: OtherOphthalmology
Modalities: Small moleculesCell therapiesGene therapiesBiomaterials (hydrogel-based)
Industry: Biotech

Drug pipeline

2 assets

GMX-101

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

HTL Biotechnology – equity investment and strategic support focused on biopolymer development and scale-up.

Beyond the preview

Go deeper on GelMEDIX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GelMEDIX.

Explore the full profile